Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc (NASDAQ: BCYC) is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC) for oncology indications. News about BCYC often centers on progress across its clinical pipeline, strategic collaborations, and financial updates that shape the company’s development plans.
Investors and observers following BCYC news can expect regular updates on clinical trials such as the Duravelo-1 Phase 1 study, the Duravelo-2 Phase 2/3 pivotal trial in metastatic urothelial cancer, and the Duravelo-3 and Duravelo-4 Phase 1/2 studies in Nectin-4–amplified breast cancer and non-small cell lung cancer. The company also reports on data presentations at major scientific meetings, including imaging and clinical data for BRC molecules targeting EphA2 and MT1-MMP.
Company news also covers strategic partnerships, including long-term arrangements with the UK Nuclear Decommissioning Authority, the United Kingdom National Nuclear Laboratory, and SpectronRx to support an end-to-end 212Pb radiopharmaceutical supply chain. Additional announcements highlight Board of Directors changes, formation and expansion of the Research and Innovation Advisory Board, and inducement grants to new employees under the 2024 Inducement Plan.
On this BCYC news page, readers can track press releases on quarterly financial results, regulatory interactions related to zelenectide pevedotin’s potential approval pathway, and anticipated milestones such as dose selection decisions and data disclosures. For those researching Bicycle Therapeutics stock, this news feed provides a centralized view of the company’s operational, clinical, and corporate developments over time.
Bicycle Therapeutics (NASDAQ: BCYC) announced leadership transitions to support its oncology pipeline. Travis Thompson becomes chief financial officer, succeeding Alethia Young who will remain interim CFO for three months and then advise. Michael Method is promoted to chief medical officer, and Michael Skynner moves from CTO to chief scientific officer.
The company said it expects strengthened operational capacity and a financial runway into 2028, will progress targeted oncology clinical programs, and plans to advance new radiopharmaceutical strategic partnerships.
Bicycle Therapeutics (NASDAQ: BCYC) reviewed 2025 progress and set 2026 priorities focused on klinical development and radiopharmaceutical supply capabilities. Key near-term items include dose selection and a potential approval pathway for zelenectide pevedotin from the Phase 2/3 Duravelo-2 trial and regulatory feedback expected in 1Q 2026. The company plans multiple clinical data readouts across 2026: Duravelo-2 dose data and Duravelo-1 follow-ups in H1 2026, Duravelo-3 initial data in H2 2026, and BT5528/BT7480 combination updates in H1 2026. Bicycle also reported first human imaging for EphA2 and MT1-MMP BRC molecules and describes emerging supply collaborations for 212Pb alongside existing 177Lu and 68Ga supply chains. The company expects financial runway into 2028 to support these priorities.
Bicycle Therapeutics (NASDAQ: BCYC) announced a 15-year contract with the UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium (RepU), plus an option to renew, intended to support a sustainable source of 212Pb for radiopharmaceutical development.
The company also disclosed partnerships with the United Kingdom National Nuclear Laboratory to scale 228Th extraction and with SpectronRx to develop a bespoke 212Pb generator; initial quantities of 212Pb have been produced. Bicycle said these arrangements aim to enable an end-to-end supply chain for its Bicycle Radioconjugates (BRC) portfolio and noted plans to present initial EphA2 human imaging data in H1 2026 and to initiate a company-led Bicycle study in 2026.
Bicycle Therapeutics (NASDAQ: BCYC) announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 18, 2025 at 10:30 a.m. GMT.
A live webcast will be accessible from the company's Investor section at www.bicycletherapeutics.com, with an archived replay available after the event.
Bicycle Therapeutics (NASDAQ: BCYC) reported Q3 2025 updates and financials on Oct 30, 2025. The company said it expects an update on dose selection for the Phase 2/3 Duravelo-2 trial and a potential approval pathway for zelenectide pevedotin in metastatic urothelial cancer after regulatory meetings in 1Q 2026. Ongoing trials Duravelo-3 (NECTIN4-amplified breast cancer) and Duravelo-4 (NECTIN4-amplified NSCLC) are open and enrolling. Clinical and imaging data for Bicycle Radioconjugates were presented at EANM and ESMO 2025. Board and Research Advisory appointments were announced to strengthen oncology expertise. Cash and cash equivalents were $648.3M as of Sept 30, 2025, with the company stating runway into 2028.
Bicycle Therapeutics (NASDAQ: BCYC) has strengthened its Board of Directors with two significant appointments in pharmaceutical leadership. Roger Dansey, M.D., former interim chief oncology officer at Pfizer and ex-CMO of Seagen, joins alongside Hervé Hoppenot, former chairman and CEO of Incyte.
Dr. Dansey brings extensive experience in drug development, having contributed to several successful cancer therapies including Keytruda and Adcetris. Under Hoppenot's leadership, Incyte grew revenues from $350 million to $4.2 billion and expanded its clinical pipeline. Both appointments bring valuable oncology research, drug development, and commercialization expertise to Bicycle's board as the company advances its proprietary bicyclic peptide technology platform.
Bicycle Therapeutics (NASDAQ: BCYC) reported Q2 2025 financial results and business updates. The company announced a strategic cost realignment including a 30% reduction in operations, primarily through workforce reductions. Key financial metrics include cash position of $721.5 million as of June 30, 2025, with runway extended into 2028, and a net loss of $79.0 million ($1.14 per share).
The company continues advancing its pipeline, with the Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer now recruiting patients. Bicycle strengthened its leadership by adding Charles Swanton to its Board of Directors and forming a new Research and Innovation Advisory Board. The company expects key program updates in H2 2025, including EphA2 human imaging data and updates on the Duravelo-2 trial following FDA meetings.
Rice Biotech Launch Pad has appointed Carolyn Ng, a business unit partner at TPG Life Sciences Innovations, to its external advisory board. Ng brings significant expertise in biotech and company building, with extensive experience guiding early to midstage companies across various therapeutic areas.
Currently leading investments at TPG Life Sciences Innovations in San Francisco, Ng serves on multiple boards including Mbrace Therapeutics, Adcendo Aps, and Bicara Therapeutics (NASDAQ: BCAX). Her appointment marks her as the 16th member of the Launch Pad's external advisory board, joining leaders from various prestigious institutions and companies.
The Rice Biotech Launch Pad, based in Houston, focuses on accelerating the translation of Rice University's health and medical technology discoveries into practical medical solutions.
Bicycle Therapeutics (NASDAQ: BCYC) announced the granting of inducement awards to eight new employees on July 1, 2025. The awards consist of non-qualified share options to purchase a total of 77,400 ordinary shares at an exercise price of $6.95 per share.
The options were granted under Bicycle's 2024 Inducement Plan and will vest over four years, with 25% vesting after one year and the remaining shares vesting monthly over the following 36 months. The grants were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Bicycle Therapeutics (BCYC)?
What is the market cap of Bicycle Therapeutics (BCYC)?
